Keirstead, Natalie D.;
Janovitz, Evan B.;
Meehan, James T.;
LeRoy, Bruce E.;
Megill, John R.;
Peterson, Richard A.;
Masson, Regis G.;
Marxfeld, Heike A.
Scientific and Regulatory Policy Committee Points to Consider*: Review of Scientific and Regulatory Policy Committee Points to Consider: Review of Current Practices for Ultrastructural Pathology Evaluations in Support of Nonclinical Toxicology Studies
Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
Medientyp:
E-Artikel
Titel:
Scientific and Regulatory Policy Committee Points to Consider*: Review of Scientific and Regulatory Policy Committee Points to Consider: Review of Current Practices for Ultrastructural Pathology Evaluations in Support of Nonclinical Toxicology Studies
Beteiligte:
Keirstead, Natalie D.;
Janovitz, Evan B.;
Meehan, James T.;
LeRoy, Bruce E.;
Megill, John R.;
Peterson, Richard A.;
Masson, Regis G.;
Marxfeld, Heike A.
Erschienen:
SAGE Publications, 2019
Erschienen in:
Toxicologic Pathology, 47 (2019) 4, Seite 461-468
Sprache:
Englisch
DOI:
10.1177/0192623319835170
ISSN:
0192-6233;
1533-1601
Entstehung:
Anmerkungen:
Beschreibung:
Anatomic pathology and clinical pathology end points are standard components of almost every nonclinical general toxicity study conducted during the risk assessment of novel pharmaceuticals and chemicals. On occasion, an ultrastructural pathology evaluation using transmission electron microscopy (TEM) may be included in nonclinical toxicity studies. Transmission electron microscopy is most commonly used when a light microscopic finding may require further characterization that could inform on the pathogenesis and/or mechanism of action. Regulatory guidance do not address the use of TEM in general study designs nor whether these assessments should be performed in laboratories conducted in compliance with Good Laboratory Practices. The Scientific and Regulatory Policy Committee of the Society of Toxicologic Pathology (STP) formed a Working Group to assess the current practices on the use of TEM in nonclinical toxicity studies. The Working Group constructed a survey sent to members of societies of toxicologic pathology in the United States, Europe, Britain, and Japan, and responses were collected through the STP for evaluation by the Working Group. The survey results and regulatory context are discussed, as are “points to consider” from the collective experience of the Working Group. This survey indicates that TEM remains an essential diagnostic option for complementing toxicologic pathology evaluations. [Box: see text]